<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944502</url>
  </required_header>
  <id_info>
    <org_study_id>E03-BUN-VITD-02/07</org_study_id>
    <nct_id>NCT00944502</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins</brief_title>
  <official_title>Multicenter Clinical Study, Phase III, Prospective, Randomized, Double-blind, Comparative to Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bunker Industria Farmaceutica Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bunker Industria Farmaceutica Ltda.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and tolerability of Vitatonus Dexa compared with dexamethasone in
      the signs and symptoms of neuralgia of various origins.

      Clinical study, randomized prospective and random in nature, with a patients diagnosed with
      neuralgia of diverse origin.

      Patients will be include in sufficient quantity to achieve the minimum of 104 evaluable
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observation of adverse events related to medication. The causality of adverse events concerning the use of medication will be given after applying the Naranjo Algorythm</measure>
    <time_frame>Ten days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy evaluation Likert scale and Visual Analogue</measure>
    <time_frame>Ten days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Neuralgia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone and complex vitamins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Vitatonus dexa injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group B: Vitatonus DEXA tablet:
1 tablet orally every 8 hours for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C: Dexamethasone Injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group D: Dexamethasone tablet:
1 tablet orally every 8 hours for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Group A: Vitatonus DEXA injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group B: Vitatonus DEXA tablets:
1 tablet orally every 8 hours for 10 days.
Group C: Dexamethasone Injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group D: Dexamethasone tablets:
1 tablet orally every 8 hours for 10 days.</description>
    <arm_group_label>Dexamethasone and complex vitamins</arm_group_label>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>Vitatonus dexa tablest</other_name>
    <other_name>Vitatonus Dexa Injectable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who consent to participate in the study by signing the ICF;

          2. Patients of any ethnic group of both sexs aged over 18 years;

          3. Patients with clinical diagnosis of neuralgia of various origins.

          4. Patients who present scores on the Visual Analogue Scale (VAS) greater than or equal
             to 4 for PAIN.

        Exclusion Criteria:

          1. Patients with known hypersensitivity to lidocaine and thiamine or any component of the
             formula;

          2. Pregnant women and nursing mothers;

          3. Hypertensive or cardiac patients;

          4. Patients with history of ulcers in the stomach or duodenum, diabetes mellitus or
             severe infections;

          5. Patients who use levodopa, salicylates, colchicine, aminoglycosides, chloramphenicol,
             anticonvusivantes or potassium supplement.

          6. Patient with a history of alcohol or use illicit drugs;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Hasan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Hasan</last_name>
      <phone>55 1149935469</phone>
      <email>r.hasan@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Rosa Hasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>July 23, 2009</last_update_submitted>
  <last_update_submitted_qc>July 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Elaine Pessoa</name_title>
    <organization>Bunker Indústria Farmacêutica Ltda.</organization>
  </responsible_party>
  <keyword>Neuralgy</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Complex Vitamins</keyword>
  <keyword>Injection</keyword>
  <keyword>Symptoms of neuralgy of various origins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

